Compare Incyte Corporation (INCY) vs Wolfspeed Inc (WOLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Wolfspeed Inc — how do they compare? Incyte Corporation trades at $117.81 (market cap $23.11B), while Wolfspeed Inc trades at $31.32 (market cap $1.53B). The key difference: Incyte Corporation is far larger — about 15.1× Wolfspeed Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, Wolfspeed Inc nearer its low. Which is the better fit depends on your goals.
| INCY | WOLF | |
|---|---|---|
Market Cap | $23.11B | $1.53B |
Sector | Health | Technology |
52-Week High | $118.52 | $73.68 |
52-Week Low | $67.38 | $1.19 |
Enterprise Value | $19.13B | $2.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
WOLF trades at $29.38, down 1.71% with bearish technical signals despite oversold RSI readings. The company shows negative profitability metrics with -79.83% net income margin and -14.54% ROE, though recent earnings beat expectations in two of three quarters. Strategic shifts toward data centers and defense markets alongside patent litigation activity create mixed sentiment.
Outlook remains challenging due to persistent losses and competitive pressures, though analyst consensus leans slightly bullish with 31.58% buy ratings. Key risks include execution on margin improvement and market share battles in the competitive semiconductor space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Wolfspeed Inc
Wolfspeed is the global leader in wide bandgap semiconductors, specializing in silicon carbide (SiC) and gallium nitride (GaN) materials and devices. It operates a vertically integrated model, controlling the entire process from raw material substrate production to advanced power modules, serving as a critical infrastructure provider for electric vehicles (EVs), renewable energy, and AI data centers.
Read more on WOLF →
